Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients

References

• Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55(2):262–70.10.1097/QAI.0b013e3181e9be6b
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.10.1097/01.qai.0000233310.90484.16
   PubMed Web of Science ®Google Scholar
• Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A: D study. Arch Intern Med. 2006;166(15):1632–41.
   PubMed Web of Science ®Google Scholar
• Willig AL, Overton ET. Metabolic consequences of HIV: pathogenic insights. Curr HIV/AIDS Rep. 2014;11(1):35–44.10.1007/s11904-013-0191-7
   PubMed Web of Science ®Google Scholar
• Powderly WG. Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep. 2012;9(3):218–22.10.1007/s11904-012-0119-7
   PubMed Web of Science ®Google Scholar
• Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011;76(16):1403–9.10.1212/WNL.0b013e31821670fb
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, Clinical Epidemiology Group from the French Hospital D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17(17):2479–86.10.1097/00002030-200311210-00010
   PubMed Web of Science ®Google Scholar
• Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360(9347):1747–8.10.1016/S0140-6736(02)11672-2
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Grima P, Borghetti A, Colafigli M, D’Avino A, Mondi A, et al. Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. J Infect. 2014;68(5):500–3.10.1016/j.jinf.2014.01.012
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491–501.10.1097/HJR.0b013e328336a150
   PubMedGoogle Scholar
• Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. Abacavir use and cardiovascular disease events. AIDS. 2011;25(16):1993–2004.10.1097/QAD.0b013e328349c6ee
   PubMed Web of Science ®Google Scholar
• Marcus JL, Neugebauer RS, Leyden WA, Chao CR, Xu L, Quesenberry CP Jr, et al. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals. J Acquir Immune Defic Syndr. 2016;71:413–419.
   Web of Science ®Google Scholar
• Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral Drugs from the 3 major drug classes: the data collection on adverse events of anti‐HIV drugs (D:A:D) study. J Infect Dis. 2010;201(3):318–30.10.1086/649521
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, Tolstrup M, Melchjorsen J, Frederiksen CA, Nielsen US, Langdahl BL, et al. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis. 2011;11:267.10.1186/1471-2334-11-267
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20(16):2043–50.10.1097/01.aids.0000247574.33998.03
   PubMed Web of Science ®Google Scholar
• Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17(6):1011–20.10.3851/IMP2305
   PubMed Web of Science ®Google Scholar
• Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K, et al. SWIFT: prospective 48-Week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis. 2013;56(11):1637–45.10.1093/cid/cis1203
   PubMed Web of Science ®Google Scholar
• Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781–4.10.1097/QAD.0b013e32833ad8b4
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother. 2013;68(6):1364–72.10.1093/jac/dkt007
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Bracciale L, Doino M, Sidella L, Farina S, Di Cristo V, et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother. 2011;66(3):682–3.10.1093/jac/dkq464
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.10.7326/0003-4819-130-6-199903160-00002
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179–93.
   PubMed Web of Science ®Google Scholar
• Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J. 2013;34(46):3538–46.10.1093/eurheartj/eht388
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18(7):905–13.10.3851/IMP2667
   PubMed Web of Science ®Google Scholar
• Achhra AC, Amin J, Hoy J, Tanuma J, Sirisanthana T, Nolan D, et al. Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and Australia. AIDS Res Treat. 2012;2012:246280.
   PubMedGoogle Scholar
• Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of antiretroviral therapy with tenofovir‐emtricitabine or abacavir‐lamivudine: a randomized, 96‐week trial. Clin Infect Dis. 2009;49(10):1591–601.10.1086/599193
   PubMed Web of Science ®Google Scholar
• Valantin MA, Bittar R, de Truchis P, Bollens D, Slama L, Giral P, et al. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother. 2010;65(3):556–61.10.1093/jac/dkp462
   PubMed Web of Science ®Google Scholar
• Friis-Moller, N, Ryom, L, Smith, C, Weber, R, Reiss, P, Dabis, F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of anti-HIV drugs (D:A:D) study. Eur J Prev Cardiol. 2016 Jan;23(2):214–223.
   PubMed Web of Science ®Google Scholar